Alto Neuroscience is a Stanford spin-out private company headquartered in the San Francisco Bay Area. Alto is developing a new generation of neural biomarker-based diagnostic tests and personalized treatments for use in psychiatry, based on a platform built from data aggregated at scale and proprietary artificial intelligence analysis tools. There currently is no objective way to diagnose psychiatric illness, nor to identify which treatment is best for an individual patient. Treatment selection is presently done by trial-and-error as there are no reliable blood tests nor objective brain measures, for example, that can inform these decisions. This results in clinical care that is highly inefficient and costly. Alto is focused on addressing this need through finding novel brain biomarkers that can define actionable subtypes of psychiatric illnesses, or inform the development and deployment of new treatments. Included in this pipeline are genetic signals relevant to brain function.